At AAAAI 2026, Robert Wood, MD, of Johns Hopkins University discusses remibrutinib, omalizumab, and OIT for treating food ...

At AAAAI 2026, Robert Wood, MD, of Johns Hopkins University School of Medicine, discusses the use of omalizumab vs OIT for treating food allergy.

The FDA has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis.

Inhaled corticosteroid (ICS) therapy was not associated with increased fracture risk in pediatric asthma patients, according ...

Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 ...

Study results suggest immune checkpoint inhibitor therapy may offer immunomodulatory benefits for patients with asthma and ...

The FDA's chief says the agency will begin offering bonuses to drug reviewers who complete their work ahead of schedule.

A survey of Scripps Health clinicians reveals that specialty and personal risk assessment of side effects drive the chronic ...

Addressing modifiable household exposures may help improve outcomes for adults with asthma, according to a recent study.

Asthma biologic use was not associated with an increase in respiratory infection risk, according to results from the 2026 ...

For children with severe OSA undergoing adenotonsillectomy, postoperative respiratory volume monitoring is feasible and can predict low minute ventilation.

Counties located closer to operational nuclear power plants have higher cancer mortality rates, according to a recent study.